Going off the last quarterly it should be $6m’ish or a bit more cash we’ll know in a few days anyway but with the burning $2m a quarter now and still talking toxicology aiming to get out the lab and into phase 1 sometime in 2021 current cash barely gets half way there.
“400% outperformance of gold standard” sounds all pretty from the lab but how many times have they used that many fold better than “gold standard” before yet they’ve left those candidates behind and no deals - MYC , breast cancer, blood cancer etc etc - feels like that “400% better than gold standard” card has been played plenty of times over the years ?
PYC Price at posting:
2.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)